Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Accenture
Citi
Julphar
US Army
Baxter
Teva
Fish and Richardson
Medtronic

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,807,861

« Back to Dashboard

Which drugs does patent 8,807,861 protect, and when does it expire?

Patent 8,807,861 protects AXIRON and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.
Summary for Patent: 8,807,861
Title:Spreading implement
Abstract: An implement 1 for applying a volume of liquid to a treatment surface can include a support 3 onto which is mounted a receptacle 2, the receptacle defining a reservoir space 4 which receives the liquid. The receptacle includes a wall 6 having a working surface that is used to spread the liquid over the treatment surface. The wall 6 is resiliently deformable so in use the working surface maintains contact with the treatment surface when spreading the liquid. The implement has a specific application in applying a transdermal lotion to the axilla area of the user. A system for transdermal administration of a physiological active agent from a liquid composition and a method of using this system are described.
Inventor(s): Bayly; Peter (Doreen, AU), Bayly; Mark Simon (Eltham North, AU), Ahlstrom; Magnus (Nunawading, AU), Watkinson; Adam Charles (Somerset, AU)
Assignee: Acrux DDS Pty Ltd. (West Melbourne, Victoria, AU)
Application Number:13/836,056
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,807,861
Patent Claim Types:
see list of patent claims
Composition; Delivery; Device; Use;

Drugs Protected by US Patent 8,807,861

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT. ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,807,861

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,177,449 Spreading implement ➤ Try a Free Trial
9,289,586 Spreading implement ➤ Try a Free Trial
8,419,307 Spreading implement ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,807,861

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007343579 ➤ Try a Free Trial
Brazil PI0720945 ➤ Try a Free Trial
Canada 2674661 ➤ Try a Free Trial
China 101636194 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Medtronic
Boehringer Ingelheim
Deloitte
US Army
QuintilesIMS
Dow
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.